Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Lukas Balek"'
Autor:
Michaela Bosakova, Sara P Abraham, Alexandru Nita, Eva Hruba, Marcela Buchtova, S Paige Taylor, Ivan Duran, Jorge Martin, Katerina Svozilova, Tomas Barta, Miroslav Varecha, Lukas Balek, Jiri Kohoutek, Tomasz Radaszkiewicz, Ganesh V Pusapati, Vitezslav Bryja, Eric T Rush, Isabelle Thiffault, Deborah A Nickerson, Michael J Bamshad, University of Washington Center for Mendelian Genomics, Rajat Rohatgi, Daniel H Cohn, Deborah Krakow, Pavel Krejci
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 11, Pp n/a-n/a (2020)
Abstract Mutations in genes affecting primary cilia cause ciliopathies, a diverse group of disorders often affecting skeletal development. This includes Jeune syndrome or asphyxiating thoracic dystrophy (ATD), an autosomal recessive skeletal disorder
Externí odkaz:
https://doaj.org/article/83076ddc0da44600bc5e023ad4e46b45
Autor:
Iva Gudernova, Silvie Foldynova-Trantirkova, Barbora El Ghannamova, Bohumil Fafilek, Miroslav Varecha, Lukas Balek, Eva Hruba, Lucie Jonatova, Iva Jelinkova, Michaela Kunova Bosakova, Lukas Trantirek, Jiri Mayer, Pavel Krejci
Publikováno v:
eLife, Vol 6 (2017)
In-cell profiling enables the evaluation of receptor tyrosine activity in a complex environment of regulatory networks that affect signal initiation, propagation and feedback. We used FGF-receptor signaling to identify EGR1 as a locus that strongly r
Externí odkaz:
https://doaj.org/article/163ec228390542f9aefa419a66246f0b
Autor:
Pavel Krejci, Anie Aklian, Marketa Kaucka, Eva Sevcikova, Jirina Prochazkova, Jan Kukla Masek, Pavol Mikolka, Tereza Pospisilova, Tereza Spoustova, MaryAnn Weis, William A Paznekas, Joshua H Wolf, J Silvio Gutkind, William R Wilcox, Alois Kozubik, Ethylin Wang Jabs, Vitezslav Bryja, Lisa Salazar, Iva Vesela, Lukas Balek
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e35826 (2012)
Receptor tyrosine kinase signaling cooperates with WNT/β-catenin signaling in regulating many biological processes, but the mechanisms of their interaction remain poorly defined. We describe a potent activation of WNT/β-catenin by FGFR2, FGFR3, EGF
Externí odkaz:
https://doaj.org/article/c0182a0e9b1847789602f32735b60daf
Autor:
Bohumil Fafilek, Peter Konik, Iva Gudernova, Jennifer Zieba, Miroslav Varecha, Sara P. Abraham, Tomas Gregor, Ivan Duran, David Šmajs, Gert Jansen, Marketa Tomanova, Pavel Krejci, So Hyun Park, Jieun Song, Tomáš Bárta, Deborah Krakow, Lukas Balek, Alexandru Nita, David Potesil, Zheng Fu, Neha Basheer, Hyuk Wan Ko, Aleš Hampl, Michaela Bosakova, Jana Kučerová, Juraj Bosák, Lukáš Trantírek, Zbynek Zdrahal
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the U.S.A., 116(10), 4316-4325. National Academy of Sciences
Proceedings of the National Academy of Sciences of the U.S.A., 116(10), 4316-4325. National Academy of Sciences
Significance A properly functioning primary cilium is prerequisite for both normal development and aging of all ciliated organisms, including humans. In vertebrates, the signaling of Hedgehog family morphogens depends entirely on primary cilium. Rece
Autor:
Marcela Buchtová, Jiri Kohoutek, Ganesh V. Pusapati, Katerina Svozilova, Isabelle Thiffault, Ivan Duran, Lukas Balek, Pavel Krejci, Sara P. Abraham, Michael J. Bamshad, Daniel H. Cohn, Deborah Krakow, Michaela Bosakova, S. Paige Taylor, Tomáš Bárta, Deborah A. Nickerson, Vitezslav Bryja, Tomasz Witold Radaszkiewicz, Eva Hrubá, Eric T. Rush, Miroslav Varecha, Alexandru Nita, Rajat Rohatgi, Jorge H. Martin
Publikováno v:
EMBO Molecular Medicine
EMBO Molecular Medicine, Vol 12, Iss 11, Pp n/a-n/a (2020)
EMBO Molecular Medicine, Vol 12, Iss 11, Pp n/a-n/a (2020)
Mutations in genes affecting primary cilia cause ciliopathies, a diverse group of disorders often affecting skeletal development. This includes Jeune syndrome or asphyxiating thoracic dystrophy (ATD), an autosomal recessive skeletal disorder. Unravel
Autor:
Lukas Balek, Lívia Eiselleová, Veronika Stepankova, Pavel Krejci, Tereza Vanova, Pavel Vanacek, Stanislav Mazurenko, Jan Brezovsky, Zbynek Prokop, Karolina Zoufalova, David Bednar, Petr Dvorak, Pavel Dvorak, Michaela Bosakova, Antonin Kunka, Zaneta Konecna, Jiri Damborsky, Radka Chaloupková, Eva Sebestova
Publikováno v:
Biotechnology and Bioengineering. 115:850-862
Fibroblast growth factors (FGFs) serve numerous regulatory functions in complex organisms, and their corresponding therapeutic potential is of growing interest to academics and industrial researchers alike. However, applications of these proteins are
Autor:
Lukáš Trantírek, Stjepan Uldrijan, Bohumil Fafilek, Michaela Bosakova, Pavel Krejci, Miroslav Varecha, Veronika Palušová, Jana Kučerová, Lukas Balek, Iva Gudernova
Publikováno v:
Oncotarget
Many tyrosine kinase inhibitors (TKIs) have failed to reach human use due to insufficient activity in clinical trials. However, the failed TKIs may still benefit patients if their other kinase targets are identified by providing treatment focused on
Autor:
Iva Vesela, Lukáš Trantírek, Stuart Turner, Miroslav Varecha, Iva Gudernova, Silvie Foldynová-Trantírková, Petr Cigler, Marcela Buchtová, Michaela Bosakova, Jan Havlik, Lars Klimaschewski, Pavel Krejci, Peter Claus, Malgorzata Zakrzewska, Lukas Balek, Mateusz Adam Krzyscik, Jitka Neburkova
Publikováno v:
Biomaterials
The blocking of specific protein-protein interactions using nanoparticles is an emerging alternative to small molecule-based therapeutic interventions. However, the nanoparticles designed as "artificial proteins" generally require modification of the
Autor:
Jennifer Zieba, Bohumil Fafilek, Miroslav Varecha, Nicole H. Cernohorsky, Lukáš Trantírek, Iva Gudernova, Alexandru Nita, Jørgen Wesche, Lucie Jonatova, Christophe Erneux, Ellen Margrethe Haugsten, Tomas Gregor, Pavel Krejci, Jitka Krenova, Martin Piskacek, Lukas Balek, Michaela Bosakova, Somadri Ghosh, Deborah Krakow, Michal Kostas
Sustained activation of extracellular signal-regulated kinase (ERK) drives pathologies caused by mutations in fibroblast growth factor receptors (FGFRs). We previously identified the inositol phosphatase SHIP2 (also known as INPPL1) as an FGFR-intera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9596a5217adb24417e9463b09d8bd9a
http://hdl.handle.net/10852/72447
http://hdl.handle.net/10852/72447
Autor:
Lukáš Trantírek, Jan M. Wit, Hermine A. van Duyvenvoorde, Monique Losekoot, Sarina G. Kant, Martine C. de Vries, Pavel Krejci, Annemieke J.M.H. Verkerk, Michiel J R van der Wielen, André G Uitterlinden, Iveta Cervenkova, Lukas Balek, Sabine E. Hannema, Gijs W E Santen, Wilma Oostdijk
Publikováno v:
Kant, S G, Cervenkova, I, Balek, L, Trantirek, L, Santen, G WE, De Vries, M C, Van Duyvenvoorde, H A, Van Der Wielen, M J R, Verkerk, A J M H, Uitterlinden, A G, Hannema, S E, Wit, J M, Oostdijk, W, Krejci, P & Losekoot, M 2015, ' A novel variant of FGFR3 causes proportionate short stature ', European Journal of Endocrinology, vol. 172, no. 6, pp. 763-770 . https://doi.org/10.1530/EJE-14-0945
European Journal of Endocrinology, 172(6), 763-770
European Journal of Endocrinology, 172(6), 763-770. Bioscientifica Ltd
European Journal of Endocrinology
European Journal of Endocrinology, 172(6), 763-770. BioScientifica Ltd.
European Journal of Endocrinology, 172(6), 763-770
European Journal of Endocrinology, 172(6), 763-770. Bioscientifica Ltd
European Journal of Endocrinology
European Journal of Endocrinology, 172(6), 763-770. BioScientifica Ltd.
ObjectiveMutations of the fibroblast growth factor receptor 3 (FGFR3) cause various forms of short stature, of which the least severe phenotype is hypochondroplasia, mainly characterized by disproportionate short stature. Testing for an FGFR3 mutatio